Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration

BACKGROUND: On September 9, 2021, the US Food and Drug Administration (FDA) issued a drug safety communication and required revisions to the Boxed Warning for Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) to include information about the risk of serious heart-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Jingjing, Xue, Xiangzhong, Shannon, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372959/
https://www.ncbi.nlm.nih.gov/pubmed/36001100
http://dx.doi.org/10.18553/jmcp.2022.28.9.1046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372959/
https://www.ncbi.nlm.nih.gov/pubmed/36001100
http://dx.doi.org/10.18553/jmcp.2022.28.9.1046

Ejemplares similares